



OAS | CICAD



**INTER-AMERICAN DRUG ABUSE
CONTROL COMMISSION**

CICAD

Secretariat for Multidimensional Security

SIXTY-SEVENTH REGULAR SESSION

July 17, 2020

Virtual session 10:00 – 12:00 hrs (Washington D.C. time)

OEA/Ser.L/XIV.1.67

CICAD/doc.2526/20

July 17, 2020

Original: English

**PARAGRAPHS FOR THE 50TH
REGULAR SESSION OF THE OAS GENERAL ASSEMBLY
OMNIBUS RESOLUTION ON MULTIDIMENSIONAL SECURITY 2020**

THE GENERAL ASSEMBLY,

RESOLVES:

1. To reiterate the commitment of member states, with the support of the Executive Secretariat of CICAD (ES-CICAD), to the principle of common and shared responsibility to address all matters related to the world drug problem, including international cooperation as an effective and necessary tool.
2. To strengthen communication, collaboration, cooperation, and the exchange of information among member states and the ES-CICAD in order to address and counter the world drug problem with a comprehensive, balanced, sustainable, and multidisciplinary approach based on technical and scientific evidence.
3. To invite all member states, through the ES-CICAD, to participate in and contribute to the process of reviewing and updating the Hemispheric Drug Strategy and its Plan of Action, coordinated by the Government of the United States of America as Chair and to be presented to CICAD at its sixty-eighth regular session in November 2020, which will take place in the Republic of Colombia, bearing in mind member state obligations under the relevant instruments of the international drug control system as well as other pertinent instruments.
4. To note the approval and conclusion of the Multilateral Evaluation Mechanism's (MEM) seventh round (2014-2018) Hemispheric Report on the evaluation of drug policies at CICAD's sixty-sixth regular session, as well as the "Drug Policies in the Americas and Gender Perspective: Findings from the seventh round of the MEM National Reports," and emphasize the value of the MEM, including its findings, as the OAS's most important tool for measuring the progress of drug control efforts of member states, and encourage countries to disseminate these reports as part of the ongoing support of the evaluation process.
5. To recall the convocation of the Inter-Governmental Working Group (IWG) to review and update the Multilateral Evaluation Mechanism (MEM) for the eighth round, and encourage all member states to actively participate in this Group, coordinated by the Government of Canada, as Chair of said group.
6. To request that the ES-CICAD continue supporting capacity building programs and activities at the local, national, and regional levels to develop, implement, and strengthen national drug strategies, plans of action and associated programming, recalling the 2019 United Nations' 62nd Session of the Commission on Narcotic Drugs (CND) Ministerial Declaration on strengthening our actions at the national, regional and international levels to accelerate the implementation of our joint commitments to address and counter the world drug problem, including the operational recommendations of the 2016 UNGASS Outcome Document.

7. Encourage member states to continue implementing and strengthening monitoring and evaluation processes for drug-related programs and policies, and encourage the ES-CICAD to support these efforts upon request.
8. To encourage member states to carry out technical and scientific, peer-reviewed research studies, supported by international cooperation where applicable, on all aspects of the world drug problem in their countries, so that the research obtained informs national drug policies, with the aim of increasing their efficiency and effectiveness.
9. To invite member states to continue strengthening or establishing, as appropriate, national drug observatories (or similar offices), and to encourage the ES-CICAD to support them, upon request, in the development of national drug information systems, networks, and scientific research, as well as enhancing cooperation between national drug observatories (or similar offices), to strengthen the exchange of drug information in the region.
10. To remind member states of their commitment to respond to the recently updated Annual Report Questionnaire (ARQ) of the United Nations Office on Drugs and Crime (UNODC), which collects data on drug production, trafficking, interdiction, and consumption trends, considering the importance of improving the comparability of reported data, and to invite the ES-CICAD to provide assistance to member states upon request.
11. To encourage member states to develop and implement scientific, evidence-based policies aimed at improving drug use prevention, early intervention, care, recovery, rehabilitation and social reintegration, taking into consideration the impact of the COVID-19 pandemic, while also bearing in mind the availability of, access to, and delivery of healthcare and social services for all individuals, including youth, who use drugs, and promoting non-stigmatizing attitudes, language, and inclusion and consideration of social contexts, and gender perspectives, as well as age groups, in promoting access to recovery support services and the availability of these demand reduction measures.
12. To encourage member states to design and implement scientific, evidence-based drug use prevention strategies starting from early childhood, with a particular emphasis on preventing adolescent drug use.
13. To consider and encourage the use of interventions that are in line with international standards when developing quality assurance systems for drug treatment programs.
14. To encourage member states to continue incorporating innovative and scientific evidence-based alternatives to incarceration initiatives for minor drug use-related offenses, and to encourage the ES-CICAD to continue providing technical assistance and exchange of good practices in this regard to those member states requesting such assistance.

15. To encourage member states to consider implementing comprehensive and sustainable alternative development programs, including, as appropriate, preventive alternative development and the participation of subnational communities and relevant organizations, in enhancing the welfare of affected and vulnerable populations.
16. To reiterate the joint commitment of member states, with support of the ES-CICAD, to appropriately mainstream gender and human rights perspectives in drug-related programs and projects, and ensure, to the extent possible, women's effective participation in the agencies and organizations in charge of drug control, and, in this sense, encourage the participation of member states in the Gender in the Criminal Justice System Program and the Inter-American Program for Strengthening Gender Equality in Drug Law Enforcement Agencies (GENLEA/CICAD), among others.
17. To strengthen coordination and cooperation among OAS member states and across the OAS bodies to counter illicit activities that facilitate transnational organized crime, such as trafficking in narcotics, firearms trafficking, money laundering, and other drug-related activities, and also to invite member states to promote and implement prevention measures, including ones designed to counter social consequences associated with the world drug problem.
18. To strengthen the capacities of counterdrug law enforcement agencies in member states to effectively counter the production, trafficking, and distribution of illicit plant-based and synthetic drugs, including new psychoactive substances (NPS) and the substances and chemicals used in their manufacture, such as through the adoption of, for example, technology for monitoring and surveillance, chemical identification, and specialized training to prosecute criminal behavior related to drugs and chemical precursors, as well as to develop and strengthen capabilities, including through international cooperation, to identify and disrupt emerging modalities, such as the use of the Internet, including the Dark Net, postal service systems, and crypto currencies, for the sale and distribution of illicit drugs.
19. To promote international cooperation to provide technical assistance and capacity building in support of member states' efforts to control the cultivation and production of those illicit drugs contributing to the world drug problem.
20. To encourage member states in the design, development, and strengthening of national early warning systems (EWS) on new psychoactive substances (NPS), synthetics, and other emerging drugs, in coordination with existing EWS at the global and regional levels, and request the ES-CICAD to provide training, technical assistance and capacity building in the development of EWS to member states that includes guidance to the applicable entities or agencies on how to use evidence in the development of national action plans that effectively counter the adverse consequences of misuse and traffic of these substances.

21. To encourage member states to consider signing and/or ratifying the Agreement Concerning Cooperation in Suppressing Illicit Maritime and Air Trafficking in Narcotic Drugs and Psychotropic Substances in the Caribbean, given that maritime drug trafficking constitutes a significant and growing threat in the region, and request that the ES-CICAD continue to provide, upon request, technical assistance and training to member states on counterdrug maritime cooperation and control.
22. To invite member states to continue engaging in the current 63rd Session of the United Nations Commission on Narcotic Drugs to consider the recommendations of the World Health Organization on cannabis and cannabis-related substances, in accordance with the Commission's decision to continue during its current sixty-third session the consideration of these recommendations, bearing in mind their complexity, in order to clarify the implications and consequences of, as well as the reasoning for, these recommendations, as well as the Commission's decision to vote at its reconvened sixty-third session in December 2020. Likewise, to encourage CICAD to promote dialogue with relevant international organizations with the aim of deepening the technical understanding and the implications of said recommendations.
23. To promote cooperation between national drug commissions, ministries of health, educational institutions, civil society, private sector stakeholders, and other competent institutions in member states, with the aim of enhancing efforts to counter the world drug problem.
24. To continue encouraging member states to support the work of the four CICAD groups of experts (Demand Reduction, Maritime Narcotrafficking, Chemical Substances and Pharmaceutical Products, and Comprehensive and Sustainable Alternative Development), and invites the ES-CICAD, upon request and when possible, to support increased participation of national experts at the annual meetings of the groups of experts.
25. To support the strengthening of the ES-CICAD, and to encourage member states, permanent observers, and other international donors to continue making voluntary financial contributions to fulfill its goals.
26. To thank and accept the offer of the Government of the Republic of Colombia to host the sixty-eighth regular session of CICAD, which will take place in November 2020.